UniQure NV: Overweight Outlook, Gene‑Therapy Upside Amid Regulatory Hurdle
UniQure NV (QURE) – gene‑therapy stock with Overweight support, a robust pipeline, and legal scrutiny; is it a high‑reward opportunity or risk?
2 minutes to read
UniQure NV
UniQure Shares Plunge 50% as FDA Rejects AMT‑130 BLA, Sparking Investor Investigation
UniQure’s share plunge after the FDA flagged AMT‑130 data highlights regulatory risk, legal investigations, and a bearish market—find out why investors are concerned.
2 minutes to read
uniQure NV Pioneers Gene Therapy Innovations, Aiming for Cures in Genetic Disorders
uniQure NV, a Dutch biotechnology company based in Amsterdam, is a leader in gene therapy, striving to develop curative treatments for severe genetic diseases such as hemophilia B and Huntington’s disease.
3 minutes to read